Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
171.22B
Market cap171.22B
Price-Earnings ratio
43.30
Price-Earnings ratio43.30
Dividend yield
2.79%
Dividend yield2.79%
Average volume
3.29M
Average volume3.29M
High today
High today
Low today
Low today
Open price
$329.01
Open price$329.01
Volume
0.00
Volume0.00
52 Week high
$346.85
52 Week high$346.85
52 Week low
$253.30
52 Week low$253.30

AMGN News

TipRanks 22h
Positive Outlook for Amgen: Buy Rating Backed by Promising Rocatinlimab and Obesity Treatment Prospects

Amgen (AMGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from Jefferies maintained a...

Seeking Alpha 2d
Amgen set for seven straight sessions of gains

Amgen (NASDAQ:AMGN) shares were on track for its seven straight sessions of gains on Monday, as the stock rose nearly 3% to $333.24 in afternoon trade. The bio...

Amgen set for seven straight sessions of gains
Benzinga 2d
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

On Saturday, Amgen Inc AMGN and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 trial program rocatinlimab in moderate to severe ato...

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

Analyst ratings

47%

of 32 ratings
Buy
46.9%
Hold
43.8%
Sell
9.4%

More AMGN News

TipRanks 2d
Positive Outlook for Amgen’s Stock Driven by Promising Rocatinlimab Trial Results

William Blair analyst Matt Phipps has maintained their bullish stance on AMGN stock, giving a Buy rating today. Matt Phipps has given his Buy rating due to a c...

TipRanks 2d
Amgen’s Rocatinlimab Faces Challenges in Atopic Dermatitis Market: Hold Rating Maintained

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at $328.00. Terence Flynn has...

TipRanks 2d
Cautious Hold Rating on Amgen Amid Rocatinlimab’s Efficacy and Safety Concerns

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on AMGN stock, giving a Hold rating on March 3. Mohit Bansal has given his Hold rating due...

TipRanks 3d
Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-...

TipRanks 4d
TKO, Nike, Amgen, Macy’s, Marathon: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (TKO) ), ( (NKE) ), ( (AMGN) ), ( (M) ) and ( (MARA) ). Here is a breakdown of their recent ratings and the rational...

Seeking Alpha 5d
Dividend Roundup: Nvidia, Amgen, Home Depot, JD.com, and more

This week's dividend activity included increased payouts from Bestbuy (BBY) and JD.com (NASDAQ:JD) as well as declarations from companies such as Amgen (NASDAQ:...

Dividend Roundup: Nvidia, Amgen, Home Depot, JD.com, and more
Quartz 5d
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.